Immatics (IMTX) has released an update. Immatics is showcasing promising advancements in its TCR-T therapy candidates targeting PRAME, with significant responses in metastatic melanoma patients and ...

The market expects Immatics (IMTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...

Jonathan Chang has given his Buy rating due to a combination of factors, including the promising results from Immatics’ ongoing clinical trials. The updated Phase I data for IMA203 and IMA203CD8, ...

Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen.

In this article, we are going to take a look at where Immatics N.V. (NASDAQ:IMTX) stands against the other best biotech stocks to buy under $20. The biotechnology industry is experiencing rapid ...

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T ...

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits ...